The FDA is examining a potential link between breast implants and anaplastic large cell lymphoma (ALCL), a rare and aggressive form of non-Hodgkin lymphoma.
The FDA is examining a potential link between breast implants and anaplastic large cell lymphoma (ALCL), a rare and aggressive form of non-Hodgkin lymphoma. Federal health officials believe the implants might increase a woman’s risk of developing ALCL in the scar tissue next to the implant. The FDA’s findings are based on a review of scientific literature dating back to 1997, which includes 60 cases of ALCL in women with breast implants. Thus far, the FDA has been unable to identify a type of implant or reason for implant that may increase a woman’s risk. To facilitate its investigation, the FDA is creating a registry with the help of the American Society of Plastic Surgeons and other expert groups.